LOGIN  |  REGISTER
FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3...

October 15
Last Trade: 0.34 -0.0061 -1.78

Demonstrated Favorable Safety Profile of REQORSA AUSTIN, Texas, Oct. 15, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today...Read more


Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

October 15
Last Trade: 3.03 -0.02 -0.66

Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose SAN JOSE, Calif., Oct. 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a...Read more


Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market...

October 15
Last Trade: 0.96 0.003 0.31

U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular...Read more


FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

October 15
Last Trade: 17.78 1.72 10.71

The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or after a platinum-based regimen Results of the pivotal Phase 3 LUNAR trial represent the first...Read more


UroGen Pharma Announces FDA Acceptance of its New Drug Application for UGN-102

October 15
Last Trade: 12.26 0.00 0.00

PDUFA goal date set for June 13, 2025 UGN-102 would be the first FDA-approved medicine for LG-IR-NMIBC, if approved PRINCETON, N.J. / Oct 15, 2024 / Business Wire / UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat...Read more


SELLAS Life Sciences Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for...

October 15
Last Trade: 1.20 -0.05 -4.00

GPS Currently Investigated in Phase 3 REGAL Trial in Adult AML Patients – Interim Analysis Anticipated in Q4 2024  RPDD Provides Eligibility for GPS to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be Transferred/Sold to Other Parties  Recent Valuations for...Read more


Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...

CLICK TO LEARN MORE

Biggest Gainers

 
CompanyChangeLast Trade
Bright Minds Biosciences 36.00 1,445.78 $38.49
ZIVO Bioscience 18.90 1,718.18 $20.00
Finch Therapeutics 10.20 566.67 $12.00
Jazz Pharmaceuticals 6.25 5.63 $117.28
HCA Healthcare 5.48 1.38 $401.26
Tenet Healthcare 4.96 3.19 $160.25
Univerl Health Services 4.89 2.22 $225.34
Crinetics Pharmaceuticals 4.50 8.47 $57.60
McKesson 4.39 0.86 $513.67
Alnylam Pharmaceuticals 4.04 1.43 $287.36
Janux Therapeutics 3.39 6.87 $52.74
Arcellx 3.10 3.57 $89.91
Globus Medical 2.86 4.02 $74.05
Waters 2.75 0.77 $360.00
DaVita 2.74 1.69 $164.57
Inari Medical 2.66 6.30 $44.86
Harrow 2.60 5.11 $53.49
Johnson & Johnson 2.50 1.55 $164.10

Highest Volume

 
CompanyVolumeLast Trade
Gritstone bio 348,093,732 $0.07
Bright Minds Biosciences 98,035,273 $38.49
Walgreens Boots Alliance 88,274,390 $10.42
Vyome 36,361,564 $0.22
Lipella Pharmaceuticals 29,339,061 $0.43
Immuneering 25,621,400 $2.31
Pfizer 21,729,600 $29.44
Rani Therapeutics 19,771,054 $2.12
Enveric Biosciences 19,379,621 $0.42
Aditxt 17,945,973 $1.12
CVS Health 14,897,220 $65.00
Hoth Therapeutics 11,527,638 $0.89
UnitedHealth 11,099,142 $556.29
PacBio 8,514,827 $2.10
Johnson & Johnson 8,502,958 $164.10
23andMe 8,476,809 $0.27
Tonix Pharmaceuticals 8,473,580 $0.14
Exelixis 8,387,922 $28.50
Bristol-Myers Squibb 7,931,301 $52.76
  • Upcoming FDA Catalysts

    • Iterum Therapeutics (NASDAQ: ITRM) PDUFA Date

      October 25, 2024
    • PTC Therapeutics (NASDAQ: PTCT) PDUFA Date

      November 13, 2024
    • Autolus Therapeutics (NASDAQ: AUTL) PDUFA Date

      November 16, 2024
    • Applied Therapeutics (NASDAQ: APLT) PDUFA Date

      November 28, 2024
    • Applied Therapeutics (NASDAQ: APLT) PDUFA Date

      November 28, 2024
    • BridgeBio Pharma (NASDAQ: BBIO) PDUFA Date

      November 29, 2024

Featured Stock

Recursion

Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities:
Edit

COPYRIGHT ©2023 HEALTH STOCKS HUB